Trial Profile
Open-Label, Phase II Study of Trastuzumab in Combination With Lapatinib (Cohort A) or Pertuzumab in Combination With Trastuzumab-emtansine (Cohort B) in Patients With HER2-positive Metastatic Colorectal Cancer: the HERACLES (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification)Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Sep 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Colon cancer; Rectal cancer
- Focus Therapeutic Use
- Acronyms HERACLES
- 21 Sep 2020 Results (n=92) of an analysis from HERACLES clinical program and other clinical trials assessing prevalence, timing of onset, and management of CNS recurrences in largest cohort of Colorectal cancer treated with anti-HER2 therapies at Niguarda Cancer Center presented at the 45th European Society for Medical Oncology Congress
- 04 Jun 2019 Results assessing use CT texture analysis (CTTA) to identify imaging biomarkers of HER2+ mCRC able to predict lesion response to therapy published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
- 29 Oct 2018 Status changed from recruiting to active, no longer recruiting.